

**THE PROSTATE PROJECT**  
**UNAUDITED REPORT AND**  
**FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2025**  
**CHARITY NO: 1078523**

**Moore (South) LLP**  
Chartered Accountants  
Suite 3, Second Floor  
Friary Court  
13-21 High Street  
Guildford  
Surrey GU1 3DG

## **THE PROSTATE PROJECT**

### **CONTENTS**

---

	<b>Page</b>
Legal and Administrative Information	<b>1</b>
Report of the Trustees	<b>2 - 10</b>
Independent Examiner's Report	<b>11</b>
Statement of Financial Activities	<b>12</b>
Balance Sheet	<b>13</b>
Notes to the Accounts	<b>14 - 23</b>

**THE PROSTATE PROJECT  
LEGAL AND ADMINISTRATIVE INFORMATION  
FOR THE YEAR ENDED 30 JUNE 2025**

---

Page 1

**TRUSTEES**

M Davies (Chairman)  
N Annels (appointed 23 January 2025)  
A Boden  
A Bolton  
S R J Bott  
M Collins  
C Critchlow  
Prof S Langley  
D Moschonas (appointed 23 January 2025)  
Prof H Pandha (resigned 23 September 2024)  
S McGuire (resigned 2 October 2025)  
C Perna  
M Perry  
A Wootton

**PRESIDENT**

T J Sharp (died December 2024)

**AMBASSADOR**

C Stokes

**PATRONS**

J Alliss  
The Bishop of Guildford  
C Brumpton  
M Buerk  
H McGrath  
V Hamilton  
K Jones  
F Kendall  
A Milton  
L Spaine  
R Thompson

**CHARITY REGISTRATION NUMBER**

1078523

**PRINCIPAL OFFICE**

Stokes Centre for Urology  
Royal Surrey County Hospital  
Egerton Road  
Guildford  
Surrey GU2 7XX

**INDEPENDENT EXAMINER**

Matthieu Bather ACA  
Moore (South) LLP  
Chartered Accountants  
Suite 3, Second Floor, Friary Court  
13-21 High Street  
Guildford, Surrey GU1 3DG

**BANKERS – CURRENT ACCOUNT**

CafCash	HSBC
25 Kings Hill Avenue	110 High Street
Kings Hill	Godalming
West Malling	Surrey
Kent ME19 4JQ	GU17 1DP

---

The Trustees present their report and the financial statements for the year ended 30 June 2025.

**GOVERNING DOCUMENT**

The organisation is an unincorporated trust, constituted under a Trust Deed dated 25 January 2025, replacing original dated 9 December 1999, and is a registered charity, number 1078523.

**TRUSTEES**

The Trustees who served from 1 July 2024 to 30 June 2025 are set out on page 1.

**RECRUITMENT AND APPOINTMENT OF TRUSTEES**

The Board of Trustees is responsible for the recruitment and appointment of Trustees. The Board seeks to ensure that they have the requisite skills between them to run the charity.

**TRUSTEE INDUCTION AND TRAINING**

Most new Trustees are already familiar with the practical work of the organisation.

New Trustees are given a short, informal training session to familiarise themselves with the charity and the context within which it operates. This covers:

- The obligations of Trustees.
- The main documents which set out the operational framework for the charity.
- Resourcing and the current financial position as set out in the latest published accounts.
- Future plans and objectives.

**AIMS AND OBJECTIVES**

The principal objectives of the charity are:

- To improve awareness of the existence of prostate cancer and its potential effects.
- To encourage men to have PSA test as appropriate followed by an MRI scan, provide advice and support to ensure early and accurate diagnosis.
- Provide support to men who have prostate cancer and their families in the management of the disease.
- To reduce inequality of the disease amongst low income and ethnic groups.
- To ensure wider recognition of the symptoms of prostate cancer and swifter action in seeking GP's and Consultant advice within the Local Cancer Network.
- To specifically help Royal Surrey County Hospital (RSCH), Royal Surrey Cancer Centre and Frimley Health Hospital maintain their status as centres of excellence in the diagnosis and treatment of prostate cancer.
- To develop a world class clinical based research centre at the Faculty of Medicine and Health at the University of Surrey.
- To brief GPs on the latest best practice for diagnosing and treating prostate cancer.
- Undertake all the above in a sustainable way to support initiatives to a net zero environment.
- Collaborative working with other charities and other organisations to achieve the above aims.

---

**AIMS AND OBJECTIVES (continued)**

This should be achieved at the lowest administrative cost which sets us apart from the other charities operating in this sector. In this respect, the charity is largely run by volunteers with no offices and low staff costs to fund. As a result, we are likely to be the most cost-effective charity operating in this sector.

**SUMMARY OF PUBLIC BENEFITS**

Prostate Cancer is the number one cancer in men in the UK. The overall role of the Prostate Project as a charity is to raise and provide funds and resources across a range of initiatives to fight, prevent and eventually eliminate this disease.

The activities of the Prostate Project are in accordance with the Charity Commission's guidance on public benefit. Our objectives and achievements primarily benefit men above the age of 45 although our work on cancer research also has a spin off on younger persons and women. The Charity's strategy focuses on six key objectives on prostate cancer as outlined below:

**1. Raising awareness – for the public (men and women) and GP's**

The Prostate Project is determined to continue its work to raise public awareness of prostate cancer to promote early diagnosis through briefings and communications to local organisations, as well as using the internet, social media, and more traditional means of information boards in public places such as libraries and shopping centres. The Prostate Project also publishes and distributes local information leaflets and booklets with content freely available on its web site. Although men are the main target audience, we know that women have a vital role in helping their partners, fathers and sons in coming forward and overcoming natural reluctance on sensitive health matters. A further challenge are ethnic minorities and low-income groups understanding that they have a much higher risk of prostate cancer, especially black men where there is double the incidence rate of white men. Although GP's have a good understanding of prostate cancer, we also want to support them in understanding new developments in diagnosis and treatment as well as the support we can offer their patients.

**2. Early Detection – PSA Testing**

Early detection is key with all cancers, and especially prostate cancer when there are often no visible symptoms of the disease. The Charity actively encourages and supports PSA (Prostate-Specific Antigen) testing in men aged 45 to 70 to ensure early diagnosis. This should be undertaken in a proper regulated clinical environment in accordance with the highest NHS and Care Quality Commission (CQC) standards. Unfortunately, there are still occasions where men may find it difficult to obtain a PSA from their GP, so in these instances we support their right to have the test and work with GP's and local clinical services to this end. The provision of mobile PSA blood testing vehicle will ensure not only routine PSA testing but will also target the missing hospital referrals due to the large numbers of men who did not come forward during the pandemic, as well as low income and ethnic groups.

**3. Research and Development**

Another goal is the creation of a world class clinical based research centre focused on new methods of early diagnosis and treatment, especially of advanced prostate cancer, and to better understand the genetic and ethnic issues of the disease. This should also be undertaken in collaboration where possible with research on a global basis. This research aspect of the Charity's work began at the University of Surrey in 2006. Some of the developments produced by the 25 strong team have shown relevance for detection and treatment of other cancers. In particular, much of this research is highly advanced and uses new technologies such as immunotherapy. Support from the Charity is provided in funding for research posts, laboratory equipment and research trials.

**4. Medical Equipment, Staff and Facilities for local hospitals**

A major aim was achieved in 2019 when the Stokes Centre for Urology was opened at the Royal Surrey NHS Foundation Trust in Guildford, which the Charity half funded at £2.6m. This provides a best in class outpatients and day treatment facility for both NHS and private patients, with additional space for research and administrative duties. We have also funded both Royal Surrey and Frimley Park hospitals with medical equipment where this would not normally be provided by the NHS. An example would be the donation of a £125,000 Echolaser in 2024 to treat benign prostate hyperplasia (BPH), thereby freeing up hospital resources to treat more urgent cases, and a Histolog (50% charity funded at £125,000) enabling excised tissue to be analysed in real time during surgery, thereby improving oncological outcomes. Funding has also been provided in the past for specialist roles such as nurses and research administrative staff.

**5. Support for Men with Prostate Cancer and their families**

We run a support group, which is accessible to anyone, to offer fellowship and support, in the form of meetings and one-to-one discussions, to men suffering from prostate cancer and their partners and families. It is vital to encourage the public to talk about prostate cancer more freely and for men to visit their GP promptly if they have concerns.

**6. Funding for the above**

Our fundraising committee works at all levels to drive funding to support the strategic objectives and projects for each year. This includes individual donations to working with local organisations (e.g. golf clubs, Lions, and Masons) who run events for us or who make us their 'preferred charity'. Our members have always been very generous in providing donations to specific causes both of their own accord and when we request funds. Major events also take an increasing role especially concerts such as at G Live in Guildford which raise a significant contribution and where we can make maximum impact on our prostate cancer awareness messaging. We also have benefitted from corporate sponsorship which continues with renewed focus.

The Charity's running costs are kept to a minimum and must be some of the lowest in the sector. This is because we are mainly staffed by volunteers with only one paid part time administrator and specialized contractors for support on such items as information technology and communications.

---

#### **ACCOUNTING PRINCIPLES**

The accounts have been prepared in accordance with the Statement of Recommended Practice on the basis of the accounting policies set out on pages 14 - 16.

#### **REVIEW OF PROGRESS, ACHIEVEMENTS AND FUTURE OBJECTIVES**

This section of the report provides a summary of the highlights and key activities of the Prostate Project over the last 12 months. It reviews progress and records achievements over that period as well as outlining objectives for next year.

#### **2024-25 KEY ACHEIVEMENTS AND HIGHLIGHTS**

1. The Mobile PSA Testing Clinic, or "Man Van", became operational in July 2024 and was formally launched on 3 September 2024. The Man Van was subsequently donated to the Royal Surrey NHS Foundation Trust in late 2024. The Prostate Project continues to provide the running costs for the mobile clinic. In addition to the partnership with RSCH, an agreement has been reached with Medefer, a CQC registered medical services provider and itself a provider to RSCH, for infrastructure support for PSA testing. The vehicle is one of the first of its kind, testing many men a year and specifically reducing inequality by targeting low income and ethnic groups which suffer higher incidence of prostate cancer. The plan is for it to operate in both a regulated NHS / private medical sector environment where it will have direct referral to hospital consultation which will speed up clinical pathway which is vital for cancer diagnosis and treatment. The most significant event was in March 2025 when the Man Van participated in the All Party Parliamentary Group on Prostate Cancer at The House of Commons (sponsored by Calvin Bailey MP and James Cleverly MP) where 40 MPs and Parliamentary staff were tested. In addition to many local events, e.g. Cranleigh Car Show, RSCH Community Day, and Shere Hill Climb, the Man Van is slated to appear at the British Motor Show and CarFest, both national events.
2. This was the third year of 3-year formal agreement with the University of Surrey to fund research activity is now in place rather than the previous ad hoc arrangement. This allows both the Charity and the University to better plan initiatives. The Charity also funded equipment, consumables and PhD student posts. The activities of the Research team are focussed on 3 main areas: Improved diagnosis; Treatment of Advanced Prostate Cancer; and the reasons behind racial variations in the incidence of the disease. The Research team also contributed to fundraising with 50km ultra challenges.
3. Fundraising continued with the most significant event being 'Paul Jones and Friends' concert at G Live in Guildford in early January. As in previous years we raised over £65,000 over two nights. Special thanks are due to Paul Jones and the artists involved, including The Real Thing and Lulu, as well as our long-term supporter, Tony Smith from Eclectic Live Music for organising and promoting the event. We also showed our new awareness animation on the risks of prostate cancer. Planning for G Live in early 2026 is already underway.
4. Golf events continue to be a major fund-raising opportunity. We are highly thankful for the continuing support from Univar and their golf day at the Belfry raised over £30,000. Similarly, John O'Gaunt in Bedfordshire continued to raise funds for us at their Jock Allen day. Thanks are also due to West Surrey Golf Club (£37,000), Cranleigh Golf Club (£13,000), and Hartley Wintney (£5,700).

---

**2024-25 KEY ACHIEVEMENTS AND HIGHLIGHTS (continued)**

5. There were numerous other fund-raising events and activities in the year. It is not possible to mention them all but we thank each and everyone involved, big or small, group or individual. However, two major events stand out which were the tribute gig for Roger Nicklin (£4,200), Surrey Masons (£10,000). We also received a donation (£2,500) from Sanaway, a washroom services company with which we will be collaborating to provide PSA testing events.
6. We also reviewed and have now re-launched our Support Group activities. The new Support Group structure focuses on individual advice, mutual support groups and eventually men's well-being during and following prostate cancer treatment. This is run by Andrew Gabriel and we thank him for his leadership and support.

The fact that the Charity is mainly run by volunteers also ensures costs are maintained at a low level with a very high proportion of donations being passed through to projects with benefit men with prostate cancer.

Overall, we are incredibly grateful to our members and supporters for keeping up and in many cases increasing their donations in these challenging times with the cost-of-living crisis. A special note of thanks must be made to the ongoing and wonderful financial support of individuals, family trusts and companies who share our goals and ambitions.

**PROGRESS REPORT AGAINST OBJECTIVES FOR 2024-25**

Aims and objectives for the financial year are set out below.

**1. General**

- We have had a full calendar of events planned and this continues going forward. This has included golf days, classic car shows, and motor vehicle events. More of these and innovations in our calendar are planned.
- Review the Trustee and Committee organisation to support the Charity's agenda. As our members become older to ensure there is succession and attraction of new volunteers. Departing and new Trustees are detailed above on page one.
- Further develop our relationship with corporate sponsors, e.g. new relationship with Sanaway, to support the Charity's objectives. We are very grateful to Univar which is our main corporate donor.

**2. Awareness of Prostate Cancer & Early Diagnosis:**

- Collaboration with a healthcare provider, Medefar, and PSA testing charities, Graham Fulford Charitable Trust, in the provision of mobile PSA testing, prostate cancer and general men's health.
- Target inequality issues in prostate cancer: specifically low income and black men where there is a higher incidence of the disease.
- Further develop and improve our online presence in providing information and support to men and their partners on prostate cancer.
- Provide further emphasis on the support of women in helping men combat prostate cancer.



### **3. Hospitals**

- Continue projects as they arise, and subject to affordability, to ensure that facilities and medical equipment for use by clinicians in our local hospitals are best in class.

### **4. Research**

Several lines of prostate cancer research are continuing to be pursued. The PhD project investigating the racial disparity in clinical outcomes in men with prostate cancer, focusing on the role of the tumour microbiome and its influence on the immune microenvironment in prostate cancers, is entering its final year. Ethnic specific microbiome profiles have been found from the study cohort of prostatectomy specimens from patients of different ethnicities and the bioinformatic analysis to get all the relevant data from this is on-going and the results being prepared for publication. The second part of this project utilising the MACSima Imaging Platform to investigate the immune response within prostate cancer specimens from Black-African, Black-Caribbean, Asian and White patients, is now nearing completion and the analysis of the images will then commence.

A second research project utilising state-of-the-art technology called GeoMx Digital Spatial Profiling (DSP) to understand the immune microenvironment and specifically the role of a subtype of white blood cells called mast cells within Neuroendocrine Prostate Cancer (NEPC) is now complete. This project was in collaboration with a research team at the Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, and the results are currently being written up for publication.

New research has been initiated to develop a novel 'prime-boost' vaccine strategy for men with high-risk prostate cancer. It uses a new cancer-killing virus (HSV5-15) developed at the University of Surrey, which strengthens the immune response against tumours. Testing of this virus in mice with established prostate tumours has already shown its ability to prime an immune response against the tumour. The next stage of this work will now develop the scheduling treatment strategy of the virus together with a boosting vaccine which contains prostate antigens to maintain the immune response against prostate cancer.

Research into the development of new prostate cancer targeting drugs (androgen receptor pathway inhibitors (ARPI)), continues with the aim to develop novel, first-in-class inhibitors targeting the oncogenic pathways that inhibit Castration-Resistant Prostate Cancer (CRPC) growth in preclinical models where Enzalutamide fails. These drug discoveries will provide renewed hope to CRPC patients who normally have very limited targeted treatment options.

Publications from the last year are below:

- Using the Conserved Hexapeptide in HOX Proteins as an Antagonist of HOX/PBX Interactions. Morgan R, Smith C, Pandha H. *Methods Mol Biol.* 2025;2889:139-153. doi: 10.1007/978-1-0716-4322-8\_10.
- Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate Cancer. Maylin ZR, Smith C, Classen A, Asim M, Pandha H, Wang Y. *Cells.* 2024 Dec 3;13(23):1999. doi: 10.3390/cells13231999.
- Decoding androgen receptor signalling: Genomic vs. non-genomic roles in prostate cancer. Asim M. *Neoplasia.* 2024 Dec;58:101066. doi: 10.1016/j.neo.2024.101066. Epub 2024 Oct 13.

---

**Other Key Items**

There have been many other items progressed and as Chairman I would like to give special thanks to the following for their contributions to the work of the Charity. Firstly, as Ambassador, Colin Stokes has continued to provide support and guidance to the Chairman and Trustees. Secondly, Mike Collins, Trustee, has been the driving force behind the successful deployment and operation of the Man Van.

**Legacy**

We are indebted to the legacy of Nigel Challis of £144,555 left to the charity in his will. The generosity is humbling. We have also received other legacies for which we are also grateful.

**Gift Aid**

We are indebted to Robin Smith for the work he does to ensure we are able to reclaim the gift aid on qualifying donations. This totalled £12,617 (2024 - £12,509) this year.

**Publicity**

Ian Blyth from C&M Marketing continue to support publicity and communications. We thank him, his associate Twiz Kay, and our own administrator, Katherine Hammersley for their hard work in supporting the charity.

**Financial matters within the Charity**

Andrew Bolton continues as Treasurer and Trustee. We thank him for his excellent financial advice and stewardship. Anthony Wooton, Trustee, has made a significant contribution in managing the charity's cash reserves.

**CHARITY OBJECTIVES FOR 2025-26**

In line with overall aims of the charity the Trustee's and the Committee have agreed the following priorities for the new financial year:

- Further improve awareness of the risks of prostate cancer and provide access to PSA testing, via the Mobile PSA Testing Unit, especially in communities who are at high risk (low-income groups and ethnic minorities)
- Grow the Support Group for patients at the Royal Surrey and Frimley Health hospitals.
- Continue to fund research and development into Prostate Cancer at the University of Surrey.
- Further develop opportunities for corporate sponsorship, especially with regard to the appeal to raise funds for research into the development of a prostate cancer vaccine
- Continue to grow the committee with volunteers with the necessary skill set, especially in technology and fundraising matters
- Maintaining fund raising in difficult economic circumstances.
- Review how we can work to net zero and reduce our impact on climate change.

**REVIEW OF FINANCIAL ACTIVITIES**

During the year the charity received donations and legacies of £476,278 (2024 - £311,614), income from trading activities of £4,070 (2024 - £13,920) and investment income of £13,034 (2024 - £14,147). Costs for raising funds totalled £27,666 (2024 - £32,414). Charitable activities costs of £466,795 (2024 - £295,092) and other costs were £4,942 (2024 - £4,685).

As a result, the charity had net outgoing resources for the year of £6,021 (2024 – incoming resources of £7,490).

The total unrestricted balance carried forward at 30 June 2025 was a surplus of £140,154 (2024 – £146,175). These Grants Funds are unrestricted funds which can be utilised at the discretion of the Trustees as long as they are spent within the restrictions of the Charity.

**GRANTS POLICY**

The Trustees only commit to a grant once they know they have received sufficient funding to cover the specific project. This is key to protecting both the Trustees and the long-term funding commitments made by the charity.

**RESERVES POLICY**

The Trustees aim to keep cash reserves covering six months support expenditure, which is approximately £20,000. Any reserves over and above that are available to give as grants.

**ORGANISATIONAL STRUCTURE**

The day to day running of the charity is undertaken by the Trustees and the wide Prostate Committee. The Trustees are responsible for the strategic direction and policy of the charity and meet as regularly as necessary. The Trustees provide their time for the day to day running of the charity on a voluntary basis.

**RISK**

The major risks to which the charity is exposed, as identified by the Trustees, have been reviewed and systems or procedures have been established to manage those risks.

---

**TRUSTEES' RESPONSIBILITIES IN RELATION TO THE FINANCIAL STATEMENTS**

The trustees are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP 2019 (FRS 102);
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The Trustees are responsible for maintaining proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charities (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by the Board of Trustees on  and signed on their behalf by:

*5/02/26*

**Martin Davies**

**INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF  
THE PROSTATE PROJECT  
FOR THE YEAR ENDED 30 JUNE 2025**

Page 11

I report to the charity's trustees on my examination of the accounts of the charity for the year ended 30 June 2025 which are set out on pages 12 to 23.

**Responsibilities and basis of report**

As the charity's trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the charity's accounts carried out under section 145 of the Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

**Independent examiner's statement**

Since the charity's gross income exceeds £250,000 your examiner must be a member of a body listed in Section 145 of the Act. I confirm that I am qualified to undertake the examination because I am a member of the ICAEW.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an Independent Examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

*Matthew Bather*

11th February 2026

.....  
Matthew Bather ACA  
Moore (South) LLP  
Chartered Accountants  
Suite 3, Second Floor  
Friary Court  
13-21 High Street  
Guildford  
Surrey, GU1 3DG

.....  
Date

**THE PROSTATE PROJECT**  
**STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME &**  
**EXPENDITURE ACCOUNT)**  
**FOR THE YEAR ENDED 30 JUNE 2025**

Page 12

	Notes	Unrestricted	Restricted	Total Funds 2025	Total Funds 2024
		£	£	£	£
<b>INCOMING RESOURCES</b>					
Donations and legacies	3	448,586	27,692	476,278	311,614
Other trading activities	4	4,070	-	4,070	13,920
Investment income		13,034	-	13,034	14,147
		<u>465,690</u>	<u>27,692</u>	<u>493,382</u>	<u>339,681</u>
<b>Total Incoming Resources</b>		<b>465,690</b>	<b>27,692</b>	<b>493,382</b>	<b>339,681</b>
<b>RESOURCES EXPENDED</b>					
Raising funds	5	27,666	-	27,666	32,414
Charitable activities	6	439,293	27,502	466,795	295,092
Other	9	4,942	-	4,942	4,685
		<u>471,901</u>	<u>27,502</u>	<u>499,403</u>	<u>332,191</u>
<b>Net outgoing resources and net movement in funds</b>		<b>(6,211)</b>	<b>190</b>	<b>(6,021)</b>	<b>7,490</b>
<b>Transfer between funds</b>		<b>190</b>	<b>(190)</b>	<b>-</b>	<b>-</b>
<b>Reconciliation of funds</b>		<b>(6,021)</b>	<b>-</b>	<b>(6,021)</b>	<b>7,490</b>
<b>Total funds brought forward</b>		<b>146,175</b>	<b>12,543</b>	<b>158,718</b>	<b>151,228</b>
<b>Total funds carried forward</b>	<b>16</b>	<b>140,154</b>	<b>12,543</b>	<b>152,697</b>	<b>158,718</b>

The financial statements include all gains and losses in the period.

The notes on pages 14 to 23 form part of these financial statements.

**THE PROSTATE PROJECT  
BALANCE SHEET  
AS AT 30 JUNE 2025**

**Page 13**

	Notes	30 June 2025 Unrestricted £	30 June 2025 Restricted £	30 June 2025 Total Funds £	30 June 2024 Total Funds £
<b>Current assets</b>					
Cash at bank		678,468	13,630	692,098	464,772
		<u>678,468</u>	<u>13,630</u>	<u>692,098</u>	<u>464,772</u>
<b>Creditors falling due within one year</b>					
Grants payable within one year	12	381,874	1,087	382,961	285,403
Accruals	12	37,560	-	37,560	20,651
		<u>419,434</u>	<u>1,087</u>	<u>420,521</u>	<u>306,054</u>
<b>Total assets less current liabilities</b>					158,718
<b>Creditors falling due after one year</b>					
Grants payable	13	118,880	-	118,880	-
<b>Net assets</b>		<u>140,154</u>	<u>12,543</u>	<u>152,697</u>	<u>158,718</u>
<b>Unrestricted funds</b>	15	140,154	-	140,154	146,175
<b>Restricted funds</b>	15	-	12,543	12,543	12,543
<b>Total Funds</b>		<u>140,154</u>	<u>12,543</u>	<u>152,697</u>	<u>158,718</u>

These financial statements were approved by the Trustees on 5/02/26 and are signed on their behalf by:



**Martin Davies**

The notes on pages 14 to 23 form part of these financial statements.

**1. ACCOUNTING POLICIES**

**a. Charity Status**

The charity is governed by a Trust Deed dated 9 December 1999. The charity was registered with the Charity Commission on that date, registered number 1078523. The address of the principal office is given in the Legal & Administration Information given on page 1 of these financial statements.

The charity contributes a public benefit as defined by FRS 102.

**b. Basis of Preparation**

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102), Charities SORP 2019 (FRS102), and the Charities Act 2011.

The financial statements are prepared on a going concern basis under the historical cost convention. The financial statements are prepared in sterling which is the functional currency, and have been rounded to the nearest pound.

**c. Going Concern**

The financial statements have been prepared on a going concern basis as the Trustees believe that no material uncertainties exist. The Trustees have considered the level of funds held and the expected level of income and expenditure for the 12 months from authorising these financial statements. The budgeted income and expenditure in addition to existing reserves is sufficient to fund the charity's future operations and for the charity to be considered a going concern.

**d. Income Recognition**

All incoming resources are included in the Statement of Financial Activities (SoFA) when the charity is legally entitled to the income, the amount can be reliably measured and it is probable that the income will be received.

Donations and other forms of voluntary income are recognised when receivable by the charity. They are typically received from former patients or from individuals who have read the newsletter. When particular needs are identified for a specific project approaches are made to local supporters of the charity, who may then make donations towards that specific project.

The income from charitable activities is recognised when it is received.

Gift aid is recognised in the period the donation it relates to was received.

Income from other trading activities is recognised when it is received.

Income from legacy is recognised.



---

**1. ACCOUNTING POLICIES (continued)**

**e. Donation of Gifts and Services**

Donated gifts and professional services are recognised as income when the charity has control over the item or received the service, any conditions associated with the donation have been met, the receipt of economic benefit from the use by the charity of the item is probable and that economic benefit can be measured reliably.

On receipt, donated gifts and professional services are recognised on the basis of the value of the gift to the charity, which is the amount the charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

No value is given to the donations which are given for subsequent auction as prizes at events due to difficulty, in many cases, of establishing a fair value of the donation.

**f. Expenditure Recognition**

All expenditure is accounted for on an accruals basis and is inclusive of irrecoverable VAT. Expenditure is recognised where there is a legal or constructive obligation to make payments to third parties, it is probable that the settlement will be required and the obligation can be measured reliably.

- Costs of raising funds comprise the costs associated with attracting voluntary income.
- Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for beneficiaries.
- Included in charitable expenditure are grants payable and payments made to third parties in furtherance of the charitable objectives of the Trust. The grants are accounted for when the Trustees have agreed to pay the grant.

Other costs include costs that are neither related to raising funds for the charity, nor part of its expenditure on charitable activities.

**g. Support Costs**

Support costs are those costs incurred in running the charity, but do not directly relate to either raising funds or charitable activities. These costs have been allocated to raising funds and charitable activities, on the bases set out in note 7.

**h. Debtors**

Trade and other debtors are recorded at settlement amount. Prepayments are valued at the amounts prepaid at balance sheet date.

**i. Cash at Bank and in Hand**

Cash at bank and in hand includes cash and short term highly liquid investments with short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

**j. Creditors**

Trade and other creditors are recognised when the charity has a present obligation resulting from past events and can be measured or estimated reliably. Creditors are recognised at their settlement amounts.

**k. Financial Instruments**

The trust only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

**l. VAT and Income Tax**

The charity is not VAT registered and is exempt from income tax.

**m. Funds**

Unrestricted reserves are funds that can be used in accordance with the charitable objects at the discretion of the Trustees.

Designated funds are funds that at the end of each year the Trustees may set aside for any specific projects they wish to fund.

Restricted reserves are funds that can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

**2. Judgements and Key Sources of Estimation Uncertainty**

In the application of the charitable company's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

The Trustees do not believe there are any judgements or estimates.

**THE PROSTATE PROJECT**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2025**

Page 17

**3. DONATIONS AND LEGACIES**

	Unrestricted	Restricted	Total 2025	Total 2024
	£	£	£	£
Donations	302,298	27,692	329,990	296,875
Legacies	146,288	-	146,288	14,739
<b>Total</b>	<b>448,586</b>	<b>27,692</b>	<b>476,278</b>	<b>311,614</b>

There was £57,252 of restricted donations received in 2024.

**4. OTHER TRADING ACTIVITIES**

	Unrestricted	Restricted	Total 2025	Total 2024
	£	£	£	£
Fundraising events	4,070	-	4,070	13,920

There was no restricted income in 2024 from other trading activities.

**5. RAISING FUNDS**

	Unrestricted	Restricted	Total 2025	Total 2024
	£	£	£	£
General				
Direct costs	5,740	-	5,740	12,210
Support costs (note 7)	21,926	-	21,926	20,204
<b>Total</b>	<b>27,666</b>	<b>-</b>	<b>27,666</b>	<b>32,414</b>

There were no restricted support costs in 2024.

**6. CHARITABLE EXPENSES**

	Unrestricted	Restricted	Total 2025	Total 2024
	£	£	£	£
Grants payable (note 8)	432,738	27,502	460,240	295,092
Salary	6,555	-	6,555	-
	<u>439,293</u>	<u>27,502</u>	<u>466,795</u>	<u>295,092</u>

In 2024 there were restricted grants of £57,252.

**THE PROSTATE PROJECT  
NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2025**

Page 18

**7. SUPPORT COSTS**

	Basis	Unrestricted	Restricted	Total 2025	Total 2024
		£	£	£	£
Printing and website	Income	10,727	-	10,727	8,198
PR costs	Income	9,000	-	9,000	9,780
Other costs	Income	2,199	-	2,199	2,226
<b>Total support costs</b>		<u>21,926</u>	<u>-</u>	<u>21,926</u>	<u>20,204</u>

There were no restricted support costs in 2024.

**8. ANALYSIS OF GRANTS PAYABLE**

	Unrestricted	Restricted	Total 2025	Total 2024
Man Van	4,578	-	4,578	20,000
Echolaser	-	-	-	102,600
Incucyte	11,737	-	11,737	11,737
Laser	-	-	-	10,000
Vaccine Development	85,000	-	85,000	-
Histolog	126,000	-	126,000	-
Sun Study	42,000	-	42,000	-
<b>Total Grants to Institutions</b>	<u>269,315</u>	<u>-</u>	<u>269,315</u>	<u>144,337</u>

	Unrestricted	Restricted	Total 2025	Total 2024
	£	£	£	£
SCRI - W Hobby	32,000	-	32,000	26,000
K Hammersley	42,000	-	42,000	26,000
PHD Smith	-	27,692	27,692	37,252
M Perry	-	-	-	49,976
C Perna	1,548	-	1,548	32,527
W Hayhurst	10,000	-	10,000	-
Senior Technician	78,000	-	78,000	-
<b>Total Grants to Individuals</b>	<u>163,548</u>	<u>27,692</u>	<u>191,240</u>	<u>171,755</u>
<b>Grants written back</b>	<u>(125)</u>	<u>(190)</u>	<u>(315)</u>	<u>(21,000)</u>
<b>Total Grants Payable</b>	<u>432,738</u>	<u>27,502</u>	<u>460,240</u>	<u>295,092</u>

**THE PROSTATE PROJECT  
NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2025**

**Page 19**

**8. ANALYSIS OF GRANTS PAYABLE (continued)**

Within grants payable for 2025 there were restricted amounts which are to be used based upon the donor's wishes; Gerald Moore Foundation of £27,692 (2024 - £37,252) and £Nil (2024 - £20,000) to be used to fund the Man Van.

The grants payable to institutions all relate to various projects carried out at Royal Surrey County Hospital and Frimley Park Hospital.

**9. OTHER COSTS**

**Governance Costs**

	Unrestricted	Restricted	Total 2025	Total 2024
	£	£	£	£
Independent Examiner's fees	4,614	-	4,614	4,398
Insurance	328	-	328	287
<b>Total other costs</b>	<b>4,942</b>	<b>-</b>	<b>4,942</b>	<b>4,685</b>

There were no restricted other costs in 2024.

**10. EMPLOYEES**

There were no employees during the period.

**11. TRANSACTIONS WITH TRUSTEES**

During the year no Trustees received any remuneration (2024 – £Nil).

4 Trustees (2024 – 1) were reimbursed expenses of £2,129 (2024 - £546) for van expenses, travel and fundraising event costs.

Unrestricted donations of £255 (2024- £210) were received from 2 (2024 – 2) Trustees during the year.

**THE PROSTATE PROJECT  
NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2025**

Page 20

**12. CREDITORS FALLING DUE WITHIN ONE YEAR**

	Unrestricted	Restricted	Total 2025	Total 2024
	£	£	£	£
Grants (see note 14)				
General	381,874	1,087	382,961	285,403
Accruals	37,560	-	37,560	20,651
	<u>419,434</u>	<u>1,087</u>	<u>420,521</u>	<u>306,054</u>

**13. CREDITORS FALLING DUE AFTER ONE YEAR**

	Unrestricted	Restricted	Total 2025	Total 2024
	£	£	£	£
Grants (see note 14)	<u>118,880</u>	<u>-</u>	<u>118,880</u>	<u>-</u>

**14. GRANTS PAYABLE**

Funds	Opening Balance £	Payments £	Additional Provision in Year £	Transfers	Closing Balance £
Unrestricted					
SCR1 – Wendy Hobby	28,152	(38,363)	32,000	20,000	41,789
Immunotherapy	13,659	-	-	(13,659)	-
PGMS Administrator	16,881	(35,369)	42,000	22,952	46,464
Sample Collector	23,390	-	-	(23,390)	-
Trainee Urologist	12,902	-	-	(12,902)	-
N Annals	18,000	-	-	(18,000)	-
Man Van	119,147	(31,508)	4,578	(1)	92,216
Probe	7,875	-	-	-	7,875
C Perna	5,651	(7,199)	1,548	-	-
Laser	10,000	(9,875)	-	(125)	-
Incucyte	-	(11,737)	11,737	-	-
Sun Study	-	(50,000)	42,000	25,000	17,000
W Hayhurst MD Degree	-	(3,590)	10,000	-	6,410
Vaccine Development	-	-	85,000	-	85,000
Histolog	-	-	126,000	-	126,000
Senior Technician	-	-	78,000	-	78,000
<b>Total Unrestricted</b>	<u>255,657</u>	<u>(187,641)</u>	<u>432,863</u>	<u>(125)</u>	<u>500,754</u>

**THE PROSTATE PROJECT  
NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2025**

Page 21

**14. GRANTS PAYABLE (continued)**

<b>Funds</b>	<b>Opening Balance £</b>	<b>Payments £</b>	<b>Additional Provision in Year £</b>	<b>Transfers</b>	<b>Closing Balance £</b>
<b>Restricted</b>					
Gerald Moore Foundation	29,746	(56,161)	27,692	(190)	1,087
<b>Total Restricted</b>	<u>29,746</u>	<u>(56,161)</u>	<u>27,692</u>	<u>(190)</u>	<u>1,087</u>
<b>Total Funds</b>	<u>285,403</u>	<u>(243,802)</u>	<u>460,555</u>	<u>(315)</u>	<u>501,841</u>
				<b>2025 £</b>	<b>2024 £</b>
Creditors due within one year				382,961	285,403
Creditors due after one year				118,880	-
				<u>501,841</u>	<u>285,403</u>

**15. FUNDS**

	<b>Balance at 1 July 2024 £</b>	<b>Income Resources £</b>	<b>Resources Expensed £</b>	<b>Transfers £</b>	<b>Balance at 30 June 2025 £</b>
<b>General Unrestricted Funds</b>	<u>146,175</u>	<u>465,690</u>	<u>(471,901)</u>	<u>190</u>	<u>140,154</u>
<b>Restricted Funds</b>					
<b>General</b>					
Gerald Moore Foundation	-	27,692	(27,502)	(190)	-
Immunology Fund	<u>12,543</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>12,543</u>
<b>Total Restricted Funds</b>	<u>12,543</u>	<u>27,692</u>	<u>(27,502)</u>	<u>(190)</u>	<u>12,543</u>

There are funds which have further restrictions, based upon the donor's wishes:

- The Gerald Moore Foundation fund relates to monies received to be used to provide a clinical specialist.
- The immunology fund and technical immune checkpoint fund are used to fund a specialist immunology nurse and related expenses.

**THE PROSTATE PROJECT  
NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2025**

**Page 22**

**15. FUNDS (continued)**

**Funds for the year ended 30 June 2024**

	Balance at 1 July 2023 £	Income Resources £	Resources Expensed £	Balance at 30 June 2024 £
<b>General Unrestricted Funds</b>	<u>138,685</u>	<u>282,429</u>	<u>(274,939)</u>	<u>146,175</u>
<b>Restricted Funds</b>				
<b>General</b>				
Gerald Moore Foundation	-	37,252	(37,252)	-
Immunology Fund	12,543	-	-	12,543
Man Van	-	20,000	(20,000)	-
<b>Total Restricted Funds</b>	<u>12,543</u>	<u>57,252</u>	<u>(57,252)</u>	<u>12,543</u>

**16. ANALYSIS OF NET ASSETS BETWEEN FUNDS**

	Current Assets £	Grants Payable in one Year £	Grants Payable after one Year £	Trade Creditors and Accruals £	Net Assets £
<b>Restricted</b>					
Immunology	12,543	-	-	-	12,543
Gerald Moore Foundation	1,087	(1,087)	-	-	-
	<u>13,630</u>	<u>(1,087)</u>	<u>-</u>	<u>-</u>	<u>12,543</u>
<b>Unrestricted</b>					
General Fund	651,903	-	-	(10,995)	640,908
<b>Designated:</b>					
- PGMS Administrator	8,733	(36,000)	(10,464)	(8,733)	(46,464)
- SCRI – W Hobby	4,332	(32,000)	(9,790)	(4,332)	(41,790)
- Man Van	13,500	(31,000)	(61,216)	(13,500)	(92,216)
- Probe	-	(7,874)	-	-	(7,874)
- Consumables	-	(17,000)	-	-	(17,000)
- W Hayhurst MD Degree	-	(5,000)	(1,410)	-	(6,410)
- Vaccine Developments	-	(85,000)	-	-	(85,000)
- Histology	-	(126,000)	-	-	(126,000)
- Senior Technician	-	(42,000)	(36,000)	-	(78,000)
	<u>678,468</u>	<u>(381,874)</u>	<u>(118,880)</u>	<u>(37,560)</u>	<u>140,154</u>
<b>Total</b>	<u>692,098</u>	<u>(382,961)</u>	<u>(118,880)</u>	<u>(37,560)</u>	<u>152,697</u>



16. ANALYSIS OF NET ASSETS BETWEEN FUNDS (continued)

Analysis of net assets between funds for year ended 30 June 2024

	Current Assets £	Grants Payable in one Year £	Trade Creditors and Accruals £	Net Assets £
<b>Restricted</b>				
Immunology	12,543	-	-	12,543
Gerald Moore Foundation	29,746	(29,746)	-	-
	<u>42,289</u>	<u>(29,746)</u>	<u>-</u>	<u>12,543</u>
<b>Unrestricted</b>				
General Fund	406,272	-	(4,440)	401,832
Designated:				
- PGMS Administrator	8,064	(16,881)	(8,064)	(16,881)
- Sample Collector	-	(23,390)	-	(23,390)
- Immunology	-	(13,659)	-	(13,659)
- SCRI – W Hobby	-	(28,152)	-	(28,152)
- C Perna	8,147	(5,651)	(8,147)	(5,651)
- Trainee Urologist	-	(12,902)	-	(12,902)
- N Annals	-	(18,000)	-	(18,000)
- Man Van	-	(119,147)	-	(119,147)
- Probe	-	(7,875)	-	(7,875)
- Laser	-	(10,000)	-	(10,000)
	<u>422,483</u>	<u>(255,657)</u>	<u>(20,651)</u>	<u>146,175</u>
<b>Total</b>	<u>464,772</u>	<u>(285,403)</u>	<u>(20,651)</u>	<u>158,718</u>

17. CONTROLLING PARTY

The Charity has no controlling party.